GlassScriptPhysician profile
Wei D Zhao
NPI 1205834405
$8,488.83
in general payments reported to CMS, 2019-2025
44 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $319 · 2021: $444 · 2022: $721 · 2023: $1,704 · 2024: $2,437 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,038 · Travel and Lodging: $214 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,038.30 |
| Travel and Lodging | $213.60 |
| Education | $185.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $868.43 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Travere Therapeutics, INC. | $796.60 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $750.18 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $694.96 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Glaxosmithkline, LLC. | $537.48 | 2019-2025 | Benlysta, Shingrix, Arexvy |
| Ardelyx, INC. | $457.94 | 2023-2025 | Ibsrela |
| Kyowa Kirin, INC. | $423.81 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $340.87 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $319.74 | 2022-2025 | |
| Axsome Therapeutics, INC. | $315.95 | 2022-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $281.27 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $278.95 | 2019-2025 | Auryxia, Vafseo |
| Lilly USA, LLC | $256.36 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Vifor Pharma, INC. | $226.03 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $193.37 | 2021-2025 | Lupkynis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.